{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:11:37Z","timestamp":1792980697447,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"am","delay-in-days":266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ajem.2021.08.038","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T13:46:20Z","timestamp":1629380780000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Immune checkpoint inhibitors: An emergency medicine focused review"],"prefix":"10.1016","volume":"50","author":[{"given":"Michael J.","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Holian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Sudhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2021.08.038_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/scientificamerican0590-62","article-title":"Adoptive immunotherapy for cancer","volume":"262","author":"Rosenberg","year":"1990","journal-title":"Sci Am"},{"issue":"7","key":"10.1016\/j.ajem.2021.08.038_bb0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist."},{"issue":"12","key":"10.1016\/j.ajem.2021.08.038_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ajem.2021.08.038_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0035","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.ajem.2021.08.038_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.ajem.2021.08.038_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed Death-1 inhibitors and cytotoxic T-lymphocyte-associated Protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ajem.2021.08.038_bb0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ajem.2021.08.038_bb0060","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.ajem.2021.08.038_bb0065","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ajem.2021.08.038_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of Immune Checkpoint Inhibitor Toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J Emerg Med"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in Cancer patients visiting the emergency Department of a Comprehensive Cancer Center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"9","key":"10.1016\/j.ajem.2021.08.038_bb0080","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajem.2021.08.038_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.ajem.2021.08.038_bb0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.ajem.2021.08.038_bb0110","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","article-title":"Neurological sequelae of cancer immunotherapies and targeted therapies","volume":"17","author":"Wick","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ajem.2021.08.038_bb0115","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies [published correction appears in JAMA Neurol. 2017 Oct 1;74(10):1271]","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ajem.2021.08.038_bb0125","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ajem.2021.08.038_bb0130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp-2020-323212","article-title":"Encephalitis as an immune-related adverse event","volume":"91","author":"Suzuki","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","article-title":"Myasthenia gravis and crisis: evaluation and management in the emergency department","volume":"53","author":"Roper","year":"2017","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2021.08.038_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin","year":"2021","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.ajem.2021.08.038_bb0155","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ajem.2021.08.038_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with Cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of Cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11912-018-0690-1","article-title":"Cardiotoxicity of immunotherapy: incidence, diagnosis, and management","volume":"20","author":"Asnani","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ajem.2021.08.038_bb0180","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung Cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ajem.2021.08.038_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology."},{"issue":"11","key":"10.1016\/j.ajem.2021.08.038_bb0190","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.ajem.2021.08.038_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0200","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung Cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest."},{"key":"10.1016\/j.ajem.2021.08.038_bb0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-030-41008-7_13","article-title":"Immune-related adverse events: pneumonitis","volume":"1244","author":"Zhong","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0210","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0215","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.cllc.2020.02.025","article-title":"Immune-related pneumonitis after Chemoradiotherapy and subsequent immune checkpoint blockade in Unresectable stage III non-small-cell lung Cancer","volume":"21","author":"Naidoo","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0220","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision Cancer therapies: a practical guide for radiologists in the new era of Cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"Radiographics."},{"issue":"2","key":"10.1016\/j.ajem.2021.08.038_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.ajem.2021.08.038_bb0230","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajem.2021.08.038_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ajem.2021.08.038_bb0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0245","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0250","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"10.1016\/j.ajem.2021.08.038_bb0255","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/emp2.12209","article-title":"Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department","volume":"1","author":"Yeung","year":"2020","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"10","key":"10.1016\/j.ajem.2021.08.038_bb0260","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of Nivolumab-induced bullous Pemphigoid: review of dermatologic toxicity associated with programmed cell death Protein-1\/programmed death Ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist."},{"issue":"10","key":"10.1016\/j.ajem.2021.08.038_bb0265","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0270","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ajem.2021.08.038_bb0280","doi-asserted-by":"crossref","first-page":"649863","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0285","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jemermed.2020.06.059","article-title":"Evaluation and management of the critically ill adult with diabetic ketoacidosis","volume":"59","author":"Long","year":"2020","journal-title":"J Emerg Med"},{"issue":"7","key":"10.1016\/j.ajem.2021.08.038_bb0290","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ajem.2021.08.038_bb0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ajem.2021.08.038_bb0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2018.09.019","article-title":"Liver toxicity in the era of immune checkpoint inhibitors: a practical approach","volume":"132","author":"Belli","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0305","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0310","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist."},{"issue":"5","key":"10.1016\/j.ajem.2021.08.038_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0320","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.ajem.2021.08.038_bb0325","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1016\/j.ajem.2021.08.038_bb0330","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMc1509362","article-title":"Immunotherapy-associated hemolytic Anemia with pure red-cell aplasia","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0335","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy","volume":"9","author":"Palla","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0340","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.ajem.2021.08.038_bb0345","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMc1110923","article-title":"Hemophilia a induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajem.2021.08.038_bb0350","first-page":"280","article-title":"More on hemophilia a induced by ipilimumab [published correction appears in N Engl J Med. 2012 Mar 15;366(11):1065]","volume":"366","author":"Lozier","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajem.2021.08.038_bb0355","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ajem.2021.08.038_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721006793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721006793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:58:54Z","timestamp":1760025534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675721006793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"alternative-id":["S0735675721006793"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2021.08.038","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors: An emergency medicine focused review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2021.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}